PMID- 36286810
OWN - NLM
STAT- MEDLINE
DCOM- 20221101
LR  - 20221101
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 94
IP  - 4
DP  - 2022 May 26
TI  - [Management of iron deficiency in chronic heart failure].
PG  - 572-578
LID - 10.26442/00403660.2022.04.201451 [doi]
AB  - Iron deficiency is frequent in patients with chronic heart failure (CHF) with a 
      prevalence of 50%, and its frequency varies depending on the study groups. The 
      presence of iron deficiency limits erythropoiesis, leading to the development of 
      anemia over time in patients with CHF, regardless of gender, race, and left 
      ventricular ejection fraction (LVEF). Observational studies demonstrate a higher 
      prevalence of iron deficiency in women and in patients with higher NYHA (New York 
      Heart Association) functional class, decreased LVEF, increased brain natriuretic 
      peptide (NT-proBNP), or increased high-sensitivity C-reactive protein. Iron 
      deficiency and anemia in patients with CHF are independently associated with a 
      decreased exercise capacity, hospitalizations for CHF, an increase in overall 
      mortality and mortality from cardiovascular diseases. The clinical significance 
      of iron deficiency requires the need to diagnose iron metabolism in all patients 
      with CHF. Current guidelines for the diagnosis and treatment of CHF indicate the 
      need to determine the level of ferritin and saturation of transferrin in all 
      patients with a suspected diagnosis of heart failure. The use of oral iron 
      therapy in patients with CHF demonstrates its low efficacy in correcting this 
      condition according to the clinical trials. At the same time the use of 
      intravenous iron therapy is safe and improves symptoms, exercise capacity and 
      quality of life in patients with heart failure with reduced ejection fraction and 
      iron deficiency, which has been shown both in international placebo-controlled 
      trials and meta-analyses. The use of iron carboxymaltose should improve CHF 
      symptoms, exercise capacity and quality of life in patients with CHF and LVEF45%. 
      Intravenous iron therapy has also been shown to reduce readmissions for CHF in 
      patients with an LVEF50% who have recently been hospitalized for worsening CHF.
FAU - Uskach, T M
AU  - Uskach TM
AUID- ORCID: 0000-0003-4318-0315
AD  - Chazov National Medical Research Center of Cardiology.
AD  - Russian Medical Academy of Continuous Professional Education.
LA  - rus
PT  - English Abstract
PT  - Journal Article
DEP - 20220526
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 9007-73-2 (Ferritins)
RN  - E1UOL152H7 (Iron)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 0 (Transferrins)
SB  - IM
MH  - Female
MH  - Humans
MH  - Anemia, Iron-Deficiency/diagnosis/drug therapy/epidemiology
MH  - C-Reactive Protein
MH  - Chronic Disease
MH  - Ferritins/therapeutic use
MH  - Heart Failure
MH  - *Iron/therapeutic use
MH  - *Iron Deficiencies/drug therapy
MH  - Natriuretic Peptide, Brain
MH  - Quality of Life
MH  - Stroke Volume
MH  - Transferrins/therapeutic use
MH  - Ventricular Function, Left
MH  - Male
MH  - Observational Studies as Topic
MH  - Controlled Clinical Trials as Topic
MH  - Meta-Analysis as Topic
OTO - NOTNLM
OT  - heart failure
OT  - intravenous iron therapy
OT  - iron deficiency
EDAT- 2022/10/27 06:00
MHDA- 2022/10/29 06:00
CRDT- 2022/10/26 09:54
PHST- 2022/05/25 00:00 [received]
PHST- 2022/05/25 00:00 [accepted]
PHST- 2022/10/26 09:54 [entrez]
PHST- 2022/10/27 06:00 [pubmed]
PHST- 2022/10/29 06:00 [medline]
AID - 10.26442/00403660.2022.04.201451 [doi]
PST - epublish
SO  - Ter Arkh. 2022 May 26;94(4):572-578. doi: 10.26442/00403660.2022.04.201451.